Impact of enhanced recovery protocols on nausea and vomiting after sleeve gastrectomy
Impact of Enhanced Recovery After Surgery (ERAS) for Sleeve Gastrectomy on Postoperative Nausea and Vomiting: Controlled Randomized Study.
This study tests if following special recovery guidelines can help reduce nausea and vomiting after weight loss surgery for people getting a sleeve gastrectomy.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 60 (estimated) |
| Ages | 18 Years to 60 Years |
| Sex | All |
| Sponsor | Minia University Academic / other |
| Locations | 1 site (Minya, Minia) |
| Trial ID | NCT05996887 on ClinicalTrials.gov |
What this trial studies
This clinical trial investigates the effectiveness of enhanced recovery after surgery (ERAS) protocols in reducing postoperative nausea and vomiting (PONV) in patients undergoing laparoscopic sleeve gastrectomy. Patients will be randomly assigned to either a standard care group or an ERAS group, both receiving a combination of antiemetic medications. The study will assess the incidence of PONV and the overall recovery experience of patients following their surgery. The trial aims to provide insights into the benefits of ERAS in improving postoperative outcomes.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 18-60 with a body mass index between 40 and 60 who are scheduled for elective sleeve gastrectomy.
Not a fit: Patients with contraindications to the medications used in the study or those with serious perioperative complications may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could significantly reduce the incidence of postoperative nausea and vomiting, enhancing recovery and patient satisfaction after bariatric surgery.
How similar studies have performed: Previous studies have shown that enhanced recovery protocols can improve postoperative outcomes, suggesting potential success for this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: \* Age: 18-60 years * Sex: Both sex * ASA Physical Status: II, III. * Body mass index: Between 40 and 60 kg/m2. * Participants: Patients who are undergoing elective Sleeve Gastrectomy Exclusion Criteria: * Patients with hypersensitivity or contraindication to haloperidol, dexamethasone, or ondansetron. * Serious complications in the perioperative period (such as shock, cardiac arrest, hemorrhage, needing transfusion). * Psychiatric disorder. * History of migraine. * Use of opioid, hormonal, anti-inflammatory, and antiemetic medication 24 h prior to surgery.
Where this trial is running
Minya, Minia
- Minia University — Minya, Minia, Egypt (Recruiting)
Study contacts
- Principal investigator: haidy S mansour, MD — Assistant professor
- Study coordinator: haidy s mansour, MD
- Email: haidy_mourad@yahoo.com
- Phone: 1221802324
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.